← boardnext 2026-08
ANRO
Alto Neurosciencedistress 3/10 · well-funded / low risk$26.71-2%today-5% from 52w high
Psychiatry / CNS 3
Lead: Major Depressive Disorder · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$264M
Runway
4.2 yrs
Shares 1y
+30%
Price & events
+55.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-2.3%
1W
+9.3%
1M
+3.9%
3M
+60.8%
6M
+770.0%
1Y
+76.7%
2Y
—
5Y
+29.0%
All
Overview
- Market Cap
- $937.36M
- Enterprise Value
- $687.48M
- Volume
- 10.46K
- 52 Week Range
- $2.57 – $28.07
- Total Shares
- 35.09M
- Float Shares
- 22.76M
- Short %
- 8.21%
- % Held by Insiders
- 4.11%
- % Held by Institutions
- 74.13%
- RVOL
- 0.02x
- Beta
- 1.07
Pipeline stages · 1 programs
ALTO-207
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 2 | ALTO-100 | Bipolar Disorder I or II With a Major Depressive Episode | 200 | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | ALTO-300 | Major Depressive Disorder | — | recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | ALTO-207 | Treatment-resistant Depression (TRD) | — | recruiting |
| 2026-02 | Phase 2 | ALTO-101 | Schizophrenia, Cognitive Impairment | 82 | recruiting |
| 2025-04-14 | Phase 2 | ALTO-203 25 μg, ALTO-203 75 μg | Major Depressive Disorder, Anhedonia | 69 | completed |
Catalyst news & presentations · 6
- early 2027Guided 70%trial initiationsecondaryPhase 3ALTO-207 · Initiate Phase 3 study of ALTO-207 in TRDSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 2ALTO-207 · Initiate Phase 2b study of ALTO-207 in TRDSEC 8-K
- mid-2026readoutPhase 2ALTO-300 · Topline results expectedSEC 8-K
- first half of 2025readoutPhase 2ALTO-203 · Topline readout for ALTO-203 in MDDSEC 8-K
- 2025-05-31partnershipCTC-501, CTC-413 · Acquired rights to CTC-501 and CTC-413 from Chase Therapeutics for $2.95M upfront and up to $71.5M in clinical, regulatory, and sales milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+32% upside) · 11 analysts
- 2026-05-18BairdOutperform
- 2026-05-14WedbushNeutral
- 2026-05-11HC Wainwright & Co.Buy
- 2026-05-11HC Wainwright& Co.Buy
- 2026-04-22Chardan CapitalBuy
- 2026-04-02HC Wainwright & Co.Buy
Competitors — Major Depressive Disorder
- NBIXNEUROCRINE BIOSCIENCES INC$17.2B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
- DFTXDefinium Therapeutics, Inc.$4.7B · D3
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- BHVNBiohaven Ltd.$2.2B · D6
- SPTXSeaport Therapeutics, Inc.$1.2B · D1
- NMRANeumora Therapeutics, Inc.$281M · D5
- HELPCYBIN INC.$175M · D5
- TNXPTonix Pharmaceuticals Holding Corp.$170M · D7
Recent news
- 2026-07-20EcoR1 Capital discloses 5.8% Alto Neuroscience (ANRO) stake in Schedule 13G - Stock Titan
- 2026-07-15Alto Neuroscience Raises Capital to Advance ALTO-207 - TipRanks
- 2026-07-14Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE - Minichart
- 2026-07-14BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28 - Moomoo
- 2026-07-14Form 424B5 Alto Neuroscience Inc For: 14 July By Investing.com - Investing.com Nigeria
- 2026-07-14Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting - TradingView
- 2026-07-14Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale - Stock Titan
- 2026-07-13Alto Neuroscience Prices $100 Million Stock Offering - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.